153758-56-6

Usage

Uses

Used in Pharmaceutical Industry:
(1,2,3,4-TETRAHYDRO-ISOQUINOLIN-1-YL)-METHANOL is used as a pharmaceutical intermediate for its potential role in the development of new drugs and biologically active molecules. Its unique tetrahydroisoquinoline ring structure provides a foundation for the synthesis of compounds that could address various medical needs.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, (1,2,3,4-TETRAHYDRO-ISOQUINOLIN-1-YL)-METHANOL is utilized as a building block for the synthesis of complex drug molecules. Its structure allows for the exploration of new chemical pathways and the creation of innovative therapeutic agents.
While the specific applications and industries for (1,2,3,4-TETRAHYDRO-ISOQUINOLIN-1-YL)-METHANOL are not explicitly detailed in the provided materials, its potential use as a pharmaceutical intermediate and its role in medicinal chemistry research suggest that it could be applied across various sectors within the pharmaceutical and biotechnology industries for drug discovery and development.

InChI:InChI=1/C10H13NO/c12-7-10-9-4-2-1-3-8(9)5-6-11-10/h1-4,10-12H,5-7H2

Upstream product

• 27311-63-3 1-Hydroxymethyl-isoquinoline 
• 41034-52-0 1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid 
• 27104-72-9 methyl isoquinoline-1-carboxylate 
• 50458-78-1 ethyl isoquinoline-1-carboxylate 
• 486-73-7 1-isoquinolinecarboxylic acid 

Relevant academic research and scientific papers

Synthesis and biological activities of a novel class of azole-containing antifungal agents

A series of novel 1,2,3,4-tetrahydroisoquinoline derived azoles has been designed and synthesized as antifungal agents which might function as inhibitors of cytochrome P-450 dependent lanosterol 14α-demethylase. In vitro tests showed that some of these compounds, especially 5b and 6b, effectively inhibit the growth of several strains of yeasts as well as molds.

INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT

The present invention relates to compounds of Formula (I) that target the MLH1 and/or PMS2 proteins that are components of the DNA Mismatch Repair (MMR) process: Formula (I) wherein R1, R2, R3, R4, R6

Discovery of Dihydropyrrolo[1,2- a]pyrazin-3(4 H)-one-Based Second-Generation GluN2C- And GluN2D-Selective Positive Allosteric Modulators (PAMs) of the N-Methyl- d -Aspartate (NMDA) Receptor

The N-methyl-d-aspartate receptor (NMDAR) is an ion channel that mediates the slow, Ca2+-permeable component of glutamatergic synaptic transmission in the central nervous system (CNS). NMDARs are known to play a significant role in basic neurological functions, and their dysfunction has been implicated in several CNS disorders. Herein, we report the discovery of second-generation GluN2C/D-selective NMDAR-positive allosteric modulators (PAMs) with a dihydropyrrolo[1,2-a]pyrazin-3(4H)-one core. The prototype, R-(+)-EU-1180-453, exhibits log unit improvements in the concentration needed to double receptor response, lipophilic efficiency, and aqueous solubility, and lowers cLogP by one log unit compared to the first-generation prototype CIQ. Additionally, R-(+)-EU-1180-453 was found to increase glutamate potency 2-fold, increase the response to maximally effective concentration of agonist 4-fold, and the racemate is brain-penetrant. These compounds are useful second-generation in vitro tools and a promising step toward in vivo tools for the study of positive modulation of GluN2C- and GluN2D-containing NMDA receptors.

COMPOUNDS WITH BRIDGEHEAD NITROGEN PART 74. NMR SPECTRA AND STEREOCHEMISTRY OF 1,3,10,10a-TETRAHYDRO-5H-OXAZOLOISOQUINOLINE AND 1,5,6,10b-TETRAHYDRO-3H-OXAZOLOISOQUINOLINE

Whereas 1,3,10,10a-tetrahydro-5H-oxazoloisoquinoline adopts an equilibrium in CDCl3 solution at 295 K in which the trans-fused conformation predominates, 1,5,6,10b-tetrahydro-3H-oxazoloisoquinoline adopts the O-inside cis-fused conformation.This difference in conformational preference has been explained partly in terms of ring-fusion strain.